CTNNB1 and neoplasm: Although no tumour or patient characteristics clearly discriminated fgADC from sgADC, sgADCs were enriched in Stage I tumours (37.5% vs. 4.4% in sgADC and fgADC respectively) and in tumours bearing CTNNB1 mutations (33.3% vs. 14.3% in sgADC and fgADC respectively) and were mainly derived from heavy smokers (Supplementary Tables 2 and 3).